Table 1.
CYP19 promoter | Primer pairs (5′–3′) | Amplification characteristics in Hs578t | Tissue-specific expression | Reference and NCBI accession number |
---|---|---|---|---|
CYP19-coding region | Fw: TGTCTCTTTGTTCTTCATGCTATTTCTC | Standard curve: | Detects all aromatase transcripts regardless of promoter utilized | Sanderson et al. 2000) |
Rv: TCACCAATAACAGTCTGGATTTCC | Efficiency: 92.8% | M22246 | ||
CYP19-I.4 | Fw: GGCTCCAAGTAGAACGTGACCAACTG | Standard curve: | Expressed in fibroblasts in the normal mammary gland | Heneweer et al. 2004) |
Rv: CAGCCCAAGTTTGCTGCCGAA | Efficiency: 101.9% | S52794 | ||
CYP19-PII | Fw: TCTGTCCCTTTGATTTCCACAG | Standard curve: | Expressed in ovaries, testes and stroma of breast cancer patients | Heneweer et al. 2004) |
Rv: GCACGATGCTGGTGATGTTATA | Efficiency: 108.9% | S52794 | ||
CYP19-I.3 | Fw: GGGCTTCCTTGTTTTGACTTGTAA | Standard curve: | Expressed in ovaries, testes and stroma of breast cancer patients | Wang et al. 2008) |
Rv: AGAGGGGGCAATTTAGAGTCTGTT | Efficiency: 95.7% | D30796 | ||
CYP19-I.7 | Fw: ACACTCAGCTTTTTCCCAACA | Standard curve: | Expressed in endothelial cells and stroma of breast cancer patients | NM_001347251 |
Rv: TTTCACCCCTTTCTCCGGTC | Efficiency: 90.7% |
Note: Fw, forward; NCBI, National Center Biotechnology Information; Rv, reverse.